El futuro es ahora: terapias prometedoras

Statins do not always allow the recommended goals to be met. Recent and future options for dyslipidemias are reviewed. Triglycerides: Pemafibrate affects triglycerides and LDL-c but has not yet shown changes in hard outcomes. Ethyl icosapentate reduced events, probably due to an anti-inflammatory effect. LDL cholesterol: Inclisiran, a synthetic small interfering RNA (siRNA), reduces LDL-c up to 83%. Confirmation of MACE reduction is lacking. PCSK9: MK-0616 is in Phase IIb. Gemcabene inhibits cholesterol and fatty acid synthesis and has anti-inflammatory properties. ANGPTL3: Evinacumab reduces triglycerides and HDL-c and is already approved for homozygous familial hypercholesterolemia. ARO_ANG3 is in Phase II. Gene therapy: Two strategies have been successfully used: gene transfer and gene editing. Lp(a): Pelacarsen, in Phase II, interferes with Lp(a) production. Olpasiran prevents Lp(a) assembly, with reductions of up to 95%. SLN360 can prevent Lp(a) production by up to 98%.